Your browser doesn't support javascript.
loading
The ReCoDe addiction research consortium: Losing and regaining control over drug intake-Findings and future perspectives.
Spanagel, Rainer; Bach, Patrick; Banaschewski, Tobias; Beck, Anne; Bermpohl, Felix; Bernardi, Rick E; Beste, Christian; Deserno, Lorenz; Durstewitz, Daniel; Ebner-Priemer, Ulrich; Endrass, Tanja; Ersche, Karen D; Feld, Gordon; Gerchen, Martin Fungisai; Gerlach, Björn; Goschke, Thomas; Hansson, Anita Christiane; Heim, Christine; Kiebel, Stefan; Kiefer, Falk; Kirsch, Peter; Kirschbaum, Clemens; Koppe, Georgia; Lenz, Bernd; Liu, Shuyan; Marxen, Michael; Meinhardt, Marcus W; Meyer-Lindenberg, Andreas; Montag, Christiane; Müller, Christian P; Nagel, Wolfgang E; Oliveria, Ana M M; Owald, David; Pilhatsch, Maximilian; Priller, Josef; Rapp, Michael A; Reichert, Markus; Ripke, Stephan; Ritter, Kerstin; Romanczuk-Seiferth, Nina; Schlagenhauf, Florian; Schwarz, Emanuel; Schwöbel, Sarah; Smolka, Michael N; Soekadar, Surjo R; Sommer, Wolfgang H; Stock, Ann-Kathrin; Ströhle, Andreas; Tost, Heike; Vollstädt-Klein, Sabine.
Afiliación
  • Spanagel R; Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Bach P; German Center for Mental Health (DZPG), Partner Site Mannheim-Heidelberg-Ulm, Germany.
  • Banaschewski T; Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Mannheim, Germany.
  • Beck A; German Center for Mental Health (DZPG), Partner Site Mannheim-Heidelberg-Ulm, Germany.
  • Bermpohl F; Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Bernardi RE; Department of Psychology, Faculty of Health, Health and Medical University Potsdam, Potsdam, Germany.
  • Beste C; Department of Psychiatry and Psychotherapy, Charité Campus St. Hedwig Hospital, Berlin, Germany.
  • Deserno L; Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Durstewitz D; Cognitive Neurophysiology, Department of Child and Adolescent Psychiatry and the University Neuropsychology Center (UNC), Dresden, Germany.
  • Ebner-Priemer U; Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Hospital and University Würzburg, Würzburg, Germany.
  • Endrass T; Department of Theoretical Neuroscience, Central Institute of Mental Health, Mannheim, Germany.
  • Ersche KD; German Center for Mental Health (DZPG), Partner Site Mannheim-Heidelberg-Ulm, Germany.
  • Feld G; Mental mHealth Lab, Institute of Sports and Sports Science, Karlsruhe Institute of Technology, Karlsruhe, Germany.
  • Gerchen MF; Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Gerlach B; German Center for Mental Health (DZPG), Partner Site Mannheim-Heidelberg-Ulm, Germany.
  • Goschke T; Faculty of Psychology, Technische Universität Dresden, Dresden, Germany.
  • Hansson AC; Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Mannheim, Germany.
  • Heim C; Department of Psychiatry, University of Cambridge, Cambridge, UK.
  • Kiebel S; Department of Clinical Psychology, Central Institute of Mental Health, Mannheim, Germany.
  • Kiefer F; Department of Clinical Psychology, Central Institute of Mental Health, Mannheim, Germany.
  • Kirsch P; Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Kirschbaum C; Faculty of Psychology, Technische Universität Dresden, Dresden, Germany.
  • Koppe G; Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Lenz B; Institute of Medical Psychology, Charité, Universitätsmedizin Berlin, Berlin, Germany.
  • Liu S; Cognitive Computational Neuroscience, Faculty of Psychology, Technische Universität Dresden, Dresden, Germany.
  • Marxen M; Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Mannheim, Germany.
  • Meinhardt MW; German Center for Mental Health (DZPG), Partner Site Mannheim-Heidelberg-Ulm, Germany.
  • Meyer-Lindenberg A; Department of Clinical Psychology, Central Institute of Mental Health, Mannheim, Germany.
  • Montag C; Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Müller CP; Department of Theoretical Neuroscience, Central Institute of Mental Health, Mannheim, Germany.
  • Nagel WE; Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Oliveria AMM; Hector Institute for Artificial Intelligence in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Owald D; Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Mannheim, Germany.
  • Pilhatsch M; German Center for Mental Health (DZPG), Partner Site Mannheim-Heidelberg-Ulm, Germany.
  • Priller J; Department of Psychiatry and Neurosciences, Campus Charité Mitte, Berlin, Germany.
  • Rapp MA; Department of Psychiatry and Psychotherapy, Technische Universität Dresden, Dresden, Germany.
  • Reichert M; Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Ripke S; Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Ritter K; German Center for Mental Health (DZPG), Partner Site Mannheim-Heidelberg-Ulm, Germany.
  • Romanczuk-Seiferth N; Department of Psychiatry and Psychotherapy, Charité Campus St. Hedwig Hospital, Berlin, Germany.
  • Schlagenhauf F; Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Schwarz E; Department of Psychiatry and Psychotherapy, University Clinic, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany.
  • Schwöbel S; Center for Information Services and High Performance Computing, Dresden, Germany.
  • Smolka MN; Department of Molecular and Cellular Cognition Research, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Soekadar SR; Institute of Neurophysiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Sommer WH; Department of Psychiatry and Psychotherapy, Technische Universität Dresden, Dresden, Germany.
  • Stock AK; Department of Psychiatry and Psychotherapy, Technical University of Munich, Munich, Germany.
  • Ströhle A; German Center for Mental Health (DZPG), Partner Site Munich-Augsburg, Germany.
  • Tost H; Social and Preventive Medicine, Research Area Cognitive Sciences, University of Potsdam, Potsdam, Germany.
  • Vollstädt-Klein S; German Center for Mental Health (DZPG), Partner Site Berlin-Potsdam, Berlin, Germany.
Addict Biol ; 29(7): e13419, 2024 Jul.
Article en En | MEDLINE | ID: mdl-38949209
ABSTRACT
Substance use disorders (SUDs) are seen as a continuum ranging from goal-directed and hedonic drug use to loss of control over drug intake with aversive consequences for mental and physical health and social functioning. The main goals of our interdisciplinary German collaborative research centre on Losing and Regaining Control over Drug Intake (ReCoDe) are (i) to study triggers (drug cues, stressors, drug priming) and modifying factors (age, gender, physical activity, cognitive functions, childhood adversity, social factors, such as loneliness and social contact/interaction) that longitudinally modulate the trajectories of losing and regaining control over drug consumption under real-life conditions. (ii) To study underlying behavioural, cognitive and neurobiological mechanisms of disease trajectories and drug-related behaviours and (iii) to provide non-invasive mechanism-based interventions. These goals are achieved by (A) using innovative mHealth (mobile health) tools to longitudinally monitor the effects of triggers and modifying factors on drug consumption patterns in real life in a cohort of 900 patients with alcohol use disorder. This approach will be complemented by animal models of addiction with 24/7 automated behavioural monitoring across an entire disease trajectory; i.e. from a naïve state to a drug-taking state to an addiction or resilience-like state. (B) The identification and, if applicable, computational modelling of key molecular, neurobiological and psychological mechanisms (e.g., reduced cognitive flexibility) mediating the effects of such triggers and modifying factors on disease trajectories. (C) Developing and testing non-invasive interventions (e.g., Just-In-Time-Adaptive-Interventions (JITAIs), various non-invasive brain stimulations (NIBS), individualized physical activity) that specifically target the underlying mechanisms for regaining control over drug intake. Here, we will report on the most important results of the first funding period and outline our future research strategy.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastornos Relacionados con Sustancias Límite: Animals / Humans País/Región como asunto: Europa Idioma: En Revista: Addict Biol Asunto de la revista: TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Año: 2024 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastornos Relacionados con Sustancias Límite: Animals / Humans País/Región como asunto: Europa Idioma: En Revista: Addict Biol Asunto de la revista: TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Año: 2024 Tipo del documento: Article País de afiliación: Alemania